View Sample PDF

The technologies that constitute molecular diagnostics-first-generation amplification, DNA probes, fluorescent in situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors, and molecular labels-are influencing the discovery of therapeutic molecules, the screening and diagnosis of patients, and the optimization of drug therapy. In the past few years, this rapidly evolving field has seen several fascinating developments. This TriMark Publications report describes the specific market segment of the in vitro diagnostics market known as molecular diagnostics and includes all of the generally accepted clinical analytical activities in use today. It examines the prevalent clinical-measurement devices, as well as their reagents and supplies as utilized in hospitals, clinics, large reference laboratories and doctor's offices. Diagnostic tests marketed primarily as over-the-counter are generally not included in this report, although there is inevitably some overlap. The main objectives of this analysis are: 1) identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing; 2) obtaining a complete understanding of the chief molecular diagnostics tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic-from their basic principles to their applications; 3) discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; and 4) focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts.

By Purchasing This Report You Will Have:

· An improved understanding of the current state and future of the molecular diagnostics market.
· The latest information on the leading companies engaged in research and development and products in the pipeline.
· The leading perspective of recent imaging developments and revelations.
· Knowledge of the molecular diagnostics market as an area of growth, research and investment.

This Report Will Cover the Following Molecular Diagnostics Technologies:

· Nucleic acid test applications.
· Blood testing and infectious diseases.
· Diagnostic testing using DNA.
· Cancer detection using PCR.
· Microbiology testing.
· Blood screening.
· SNPs in clinical diagnostics.
· Industrial testing and food diagnostics.
· Forensics market.
· Bioterrorism and molecular diagnostics.
· Cystic fibrosis testing.
· HLA sequencing-based typing kits
· Cytogenetic testing.
· Developments in biochips for clinical applications.
· Pharmacogenomics.

Analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research into the molecular diagnostics arena provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible research and development budgets. Company-specific information, including sales figures, product pipeline status and research and development trends is provided throughout the report. The report will:

· Assess the molecular diagnostics market drivers and bottlenecks, from the perspective of the medical and scientific communities.
· Discuss the potential benefits of the molecular diagnostics market for various sectors of the medical and scientific community.
· Establish the current total market size and future growth of the molecular diagnostics market and analyze the current size and growth of various segments.
· Provide current and forecasted market shares by company.
· Discuss profit/business opportunities by imaging segment.
· Provide strategic recommendations for near-term business opportunities.
· Assess current commercial uses of the molecular diagnostics market.
· Assess the molecular diagnostics business models.

This report answers the following questions:

· What are the near-term business opportunities in the molecular diagnostics market?
· What are the current and forecasted sizes of the molecular diagnostics market?
· What are the business models currently used by companies in molecular diagnostics?
· How will manufacturers, researchers, physicians, patients and payers influence the molecular diagnostics market?
· What are the drivers and bottlenecks influencing the molecular diagnostics market?
· What are the technologies used in the molecular diagnostics sector?
· Who holds the proprietary rights to molecular diagnostics market technology?
· What are current applications of this technology?
· What regulatory processes must molecular diagnostics undergo in the United States (U.S.), Japan and Europe?
· How will new molecular diagnostics change treatment and payment paradigms?
· How will molecular diagnostics reduce healthcare expenditures?

1. 1. Overview 9
2. 1.1 Statement of Report 9
3. 1.2 About This Report 9
4. 1.3 Scope of the Report 9
5. 1.4 Objectives 9
6. 1.5 Methodology 10
7. 1.6 Executive Summary 12
9. 2. Introduction to Molecular Diagnostics and PCR Technology 15
10. 2.1 Science Overview: Introduction to Genomics and Its Opportunity 15
11. 2.2 Impact of the Human Genome Project on Molecular Diagnostics 17
12. 2.3 Considerations for Molecular and Clinical Diagnosis 18
13. 2.4 Molecular Diagnosis in the Post-Genomic Era 19
14. 2.5 Advances in Molecular Diagnostics Technologies 20
15. 2.6 Genetic Variability and Disease 22
16. 2.7 Major Technology Platforms 22
17. 2.7.1 Gene-based Amplification Technologies 23
18. 2.7.2 Detection of Amplified Gene Products 23
19. 2.7.3 Target-Based Gene Amplification 24
20. 2.7.3.1 Polymerase Chain Reaction 24
21. 2.7.3.2 Real-time PCR 25
22. 2.7.3.3 Nucleic Acid Sequence-Based Amplification 26
23. 2.7.4 Probe-Based Amplification 26
24. 2.7.4.1 Ligase Chain Reaction 26
25. 2.7.4.2 Strand Displacement Amplification 26
26. 2.7.4.3 Qß-replicase Amplified Probe Assay 26
27. 2.7.5 Signal-Based Amplification 27
28. 2.7.5.1 Branched DNA (bDNA) 27
29. 2.7.6 Other Gene Amplification Technologies 27
30. 2.7.6.1 Immuno-PCR 27
31. 2.7.6.2 Bio-Barcode Assay 27
33. 3. Nucleic Acid Test Applications 29
34. 3.1 Blood Testing and Infectious Diseases 30
35. 3.1.1 Molecular Diagnostics Market 30
36. 3.1.1.1 Methods for DNA Detection and Gene Sequencing 41
37. 3.1.1.2 Products and Applications 42
38. 3.1.1.3 Oncology 43
39. 3.1.2 SNPs and Genes: Medical Utility (Clinical Applications) 43
40. 3.1.2.1 Clinical Application Initiatives 45
41. 3.1.2.2 A Sampling of Clinical Application Collaborations 46
42. 3.1.2.3 Collaborative Relationships 48
43. 3.2 Diagnostic Testing Using DNA 49
44. 3.2.1 HIV 51
45. 3.2.2 Hepatitis Serologic Markers and Nucleic Acid Testing 53
46. 3.2.2.1 Hepatitis A Virus (HAV) 53
47. 3.2.2.2 Hepatitis B Virus (HBV) 54
48. 3.2.2.3 Hepatitis C Virus (HCV) 57
49. 3.2.2.4 Hepatitis D Virus (HDV) 62
50. 3.2.2.5 Hepatitis E Virus (HEV) 62
51. 3.2.2.6 HBV/HCV Viral Load and Drug Resistance 62
52. 3.2.3 Severe Acute Respiratory Syndrome (SARS) 64
53. 3.2.3.1 New Approach to Diagnosing Avian Influenza 65
54. 3.2.3.2 Microarray or DNA Chip-Based Tests 67
55. 3.2.4 Cancer Detection Using PCR 68
56. 3.2.4.1 Lung Cancer 68
57. 3.2.4.2 Oral Cancer 69
58. 3.2.4.3 Prostate Cancer 69
59. 3.2.4.4 Chronic Myelogenous Leukemia 69
60. 3.2.4.5 Malignant Gliomas 70
61. 3.2.4.6 Colorectal Cancer 70
62. 3.2.4.7 Breast Cancer 70
63. 3.2.4.8 Bladder Cancer 70
64. 3.2.5 Microbiology Testing 70
65. 3.2.5.1 Chlamydia 71
66. 3.2.5.2 Gonorrhea 71
67. 3.2.5.3 Tuberculosis 71
68. 3.2.5.4 Group B Streptococcus 74
69. 3.2.5.5 Pathogenic Enteric Bacteria 76
70. 3.2.5.6 Bordetella pertussis 77
71. 3.2.5.7 Legionella Pneumophila 77
72. 3.2.5.8 Peridontal Bacteria 77
73. 3.2.5.9 Pneumocystis Carinii 77
74. 3.2.5.10 Methicillin-resistant Staphylococcus Aureus 78
75. 3.2.6 Blood Screening 78
76. 3.3 SNPs in Clinical Diagnostics 83
77. 3.3.1 Functional Genomics 87
78. 3.3.2 Paternity Testing 87
79. 3.4 Industrial Testing and Food Diagnostics 88
80. 3.4.1 The Market 88
81. 3.4.2 Detection of H. pylori by PCR 91
82. 3.4.3 Detection of E. coli 0157 91
83. 3.4.4 Detection of Enteric Viruses 91
84. 3.5 Forensics Market 92
85. 3.5.1 Isolation of DNA for PCR Profiling 93
86. 3.5.2 Analysis by PCR-Based DNA Typing 94
87. 3.5.3 Rapid Isolation of DNA for RFLP and PCR 94
88. 3.5.4 DNA for PCR-STR Typing 94
89. 3.6 Bioterrorism and Molecular Diagnostics 94
90. 3.6.1 Introduction 94
91. 3.6.1.1 Current Biological Threat Detection Systems 97
92. 3.6.1.2 Use of DNA Microarrays and Biochips for Gene Expression Profiles in BWA 98
93. 3.6.1.3 Advantages and Disadvantages of Host Gene Expression Profiling as a Biothreat Detection System 99
94. 3.6.2 Biological Warfare Agents 100
95. 3.6.2.1 Anthrax 100
96. 3.6.2.2 Botulinum Toxin 101
97. 3.6.2.3 Ricin 101
98. 3.6.2.4 IVD Industry and Bioterrorism Preparedness 101
99. 3.6.2.4.1 Brucellosis 101
100. 3.6.2.4.2 Cholera 102
101. 3.6.2.5 Rapid Lateral Flow Immunoassays 103
102. 3.6.2.6 Biosensors 104
103. 3.6.2.6.1 Antibody and Synthetic Receptor-Based Sensors 104
104. 3.6.2.6.2 DNA Sensors 105
105. 3.6.2.6.3 Reagentless Sensors 106
106. 3.6.3 Anthrax in Clinical Samples 107
107. 3.6.3.1 Overview of Anthrax and Its Infectivity 107
108. 3.6.3.2 Rapid Tests 109
109. 3.6.3.2.1 PCR Tests 109
110. 3.7 Cystic Fibrosis Testing 110
111. 3.8 HLA Sequencing-Based Typing Kits 112
112. 3.9 Cytogenetic Testing 114
113. 3.9.1 Hereditary Hemochromatosis 116
114. 3.9.2 Apolipoprotein E (ApoE) Genotyping 116
115. 3.9.3 Fragile X Syndrome 117
116. 3.9.4 Methylenetetrahydrofolate Reductase (MTHFR) Carrier Testing 118
117. 3.10 Developments in Biochips for Clinical Applications 119
118. 3.10.1 Roche AmpliChip Microarray 119
119. 3.10.2 Breast Cancer DNA Chips 119
120. 3.10.3 eSensor DNA Detection System 120
121. 3.11 Pharmacogenomics 121
122. 3.11.1 Coumadin 122
123. 3.12 Thrombic Disorders 124
125. 4. Trends in Molecular Diagnostics 125
126. 4.1 Pharmacogenomics 125
127. 4.1.1 The Market 125
128. 4.1.1.1 Oncology 125
129. 4.1.1.2 Toxicogenomics 125
130. 4.1.2 Market Influences and Forecast 126
131. 4.2 DNA Microarrays 126
132. 4.2.1 Techniques 131
133. 4.2.2 The Market 131
134. 4.2.3 Identification of Sequence SNPs 131
135. 4.2.4 Determining Gene Expression Levels 132
136. 4.2.4.1 Hybridization Tests 132
137. 4.2.4.2 Oligonucleotide Probes 133
138. 4.2.5 Molecular Diagnostics Entry into Point-of-Care Testing 133
139. 4.3 Emerging Markets of DNA Arrays 133
140. 4.3.1 Pharmacogenomics 135
141. 4.3.2 Adoption of Amplified Screening Technology 135
142. 4.3.3 Advances in Automated Testing 135
143. 4.3.4 Increased Focus on Safety of Blood Supply 136
144. 4.3.5 Development of Emerging Markets for NAT Technology 136
145. 4.3.6 Cancer 136
146. 4.3.7 Human Leukocyte Antigen Typing 136
147. 4.3.8 Neonatal Screening 137
148. 4.4 Drivers and Restraints 138
149. 4.5 Market Forecast 139
150. 4.6 Business Trends in the Industry 139
151. 4.6.1 Molecular Diagnostics Industry Trends 139
152. 4.6.1.1 Adoption of Amplified Screening Technology 139
153. 4.6.1.2 Advances in Automated Testing 139
154. 4.6.1.3 Responsiveness to Newly Emerging Threats 140
155. 4.6.1.4 Increased Focus on Safety of Blood Supply 140
156. 4.6.1.5 Growth in Viral Load Testing 140
157. 4.6.1.6 Development of Emerging Markets for NAT Technology 140
158. 4.6.1.7 Improvements in Detection Technologies 141
159. 4.6.2 Pharmaceutical Industry Trends 141
160. 4.6.3 Acquisitions, License Agreements and Partnerships 143
161. 4.6.4 Ethical, Legal and Social Issues Related to the Use of Genetic Information 146
162. 4.6.5 Regulatory Issues 146
163. 4.6.6 Reimbursement Issues 147
164. 4.6.6.1 Cystic Fibrosis 147
165. 4.6.6.2 Viral Load Testing 147
166. 4.6.6.3 NMP22 147
167. 4.6.6.4 iFOB Reimbursement 147
169. 5. Molecular Diagnostics Automated Instrumentation Approved for Market by the FDA 148
170. 5.1 Gene Expression Profiling 149
171. 5.2 Proteomic Multiplex Assays 149
172. 5.3 Solution-Phase Multiplexing 149
173. 5.4 RNA Interference (RNAi) 150
174. 5.4.1 Role of RNAi in Drug Target Validation 151
175. 5.4.2 Other Companies Involved in the RNAi Market 151
176. 5.5 DNA Tags 152
178. 6. Market Trends and Forecasts 153
179. 6.1 Market Dynamics 153
180. 6.1.1 Technological Perspective on Molecular Diagnostics 153
181. 6.1.2 Molecular Diagnostics Market Opportunities 153
182. 6.1.3 Market Forces 154
183. 6.1.3.1 Adoption of Amplified Screening Technology 155
184. 6.1.3.2 Advances in Automated Testing 155
185. 6.1.3.3 Responsiveness to Newly Emerging Threats 155
186. 6.1.3.4 Increased Focus on Safety of Blood Supply 156
187. 6.1.3.5 Growth in Viral Load Testing 156
188. 6.1.3.6 Development of Emerging Markets for NAT Technology 156
189. 6.1.3.7 Improvements in Detection Technologies 157
190. 6.2 Future Considerations for Molecular Diagnosis 157
191. 6.3 Role of Genomics in Transforming Pharmaceutical R&D 158
192. 6.4 Cancer Markers 158
193. 6.5 Cytology Markers 159
194. 6.6 RNA Detection 159
195. 6.7 Diagnosis of Inherited Disease 159
196. 6.8 Ethical Considerations 159
197. 6.9 NAT and Personalized Medicine 161
198. 6.10 Five Molecular Diagnostics Growth Areas 161
199. 6.11 Specific Commercial Nucleic Acid Probes 161
200. 6.12 Novel Amplification Techniques in the Market 162
201. 6.13 Ramification Amplification Method (RAM) 163
202. 6.14 Invader Assays/Third Wave Technologies 163
203. 6.15 Molecular Beacons 165
204. 6.16 HLA Sequencing-Based Typing Kits 166
205. 6.17 Prenatal Diagnosis 166
206. 6.18 Newborn Screening 167
207. 6.19 NAT and Preventive Medicine: NAT-Based Assays 167
208. 6.20 Prenatal and Pre-implantation Diagnosis 168
209. 6.21 FISH-Based Tests on Fetal Cells 168
210. 6.22 Companion Therapeutic/Diagnostic Approach 168
211. 6.23 Sample Preparation Market 169
213. 7. Corporate Directory 170
214. 7.1 Abbott Laboratories 170
215. 7.2 Affymetrix 174
216. 7.3 Agendia 182
217. 7.4 Agilent Technologies 182
218. 7.5 Ambion 183
219. 7.6 Applied Biosystems Group 183
220. 7.7 Beckman Coulter 187
221. 7.8 BioGenex 190
222. 7.9 bioMérieux 190
223. 7.10 Bio-Rad Laboratories 190
224. 7.11 Biotage 191
225. 7.12 Biotest 191
226. 7.13 Caliper Life Sciences 192
227. 7.14 Celera Group 194
228. 7.15 Cellomics 195
229. 7.16 Cepheid 195
230. 7.17 Chiron (Novartis) 196
231. 7.18 Ciphergen Biosystems 197
232. 7.19 CuraGen 198
233. 7.20 Cytocell Technologies 203
234. 7.21 Dako A/S (formerly DakoCytomation A/S) 203
235. 7.22 DiaDexus 204
236. 7.23 Digene 206
237. 7.24 Enzo Biochem 206
238. 7.25 Epigenomics 206
239. 7.26 Epoch Biosciences 207
240. 7.27 EraGen Biosciences 207
241. 7.28 Eurogentec 207
242. 7.29 Exiqon 208
243. 7.30 Gene Link 208
244. 7.31 Gene Logic 208
245. 7.32 GeneOhm Sciences 210
246. 7.33 Genisphere 211
247. 7.34 Gen-Probe 211
248. 7.35 Genzyme 213
249. 7.36 Hamilton Thorne Biosciences 214
250. 7.37 ID Biomedical 214
251. 7.38 Illumina 215
252. 7.39 Incyte 218
253. 7.40 Innogenetics 220
254. 7.41 Interleukin Genetics 221
255. 7.42 Invitrogen 222
256. 7.43 Kreatech Biotechnology 224
257. 7.44 LabCorp 224
258. 7.45 LI-COR Biosciences 224
259. 7.46 Matritech 225
260. 7.47 Meridian Bioscience 227
261. 7.48 Monogram Biosciences 228
262. 7.49 Motorola 230
263. 7.50 MWG Biotech 231
264. 7.51 Myriad Genetics 231
265. 7.52 Nanogen 233
266. 7.53 Nanosys 235
267. 7.54 NimbleGen Systems 236
268. 7.55 Nuvelo 236
269. 7.56 Nymox Pharmaceutical 237
270. 7.57 Orchid BioSciences 238
271. 7.58 Orchid Cellmark 238
272. 7.59 Organon International 241
273. 7.60 Ortho-Clinical Diagnostics 241
274. 7.61 Ostex International 243
275. 7.62 PerSeptive Biosystems 243
276. 7.63 PharMingen 243
277. 7.64 PPD 243
278. 7.65 PPGx (DNA Sciences Laboratories) 244
279. 7.66 Prodesse 244
280. 7.67 Professional Genetics Laboratory 244
281. 7.68 Promega 245
282. 7.69 QIAGEN 245
283. 7.70 Quantum Biotechnologies 248
284. 7.71 Quidel 248
285. 7.72 Response Biomedical 250
286. 7.73 Roche Diagnostics 250
287. 7.74 Siemens 253
288. 7.75 Sequenom 254
289. 7.76 SurModics 256
290. 7.77 Tepnel Life Sciences 257
291. 7.78 Thermo Fisher Scientific 257
292. 7.79 Third Wave Technologies 258
293. 7.80 Tm Bioscience 259
294. 7.81 Visible Genetics 259
295. 7.82 VisiGen Biotechnologies 260
296. 7.83 Vysis 260
297. 7.84 Alternative Sequencing Companies 260
298. 7.84.1 Callida Genomics, Inc. 260
299. 7.84.2 Mobious Genomics, Ltd. 260
300. 7.84.3 Perlegen Sciences, Inc. 260
301. 7.84.4 Solexa, Ltd. 261
302. 7.84.5 U.S. Genomics, Inc. 261
304. 8. Market Overview 262
305. 8.1 Snapshot of Molecular Diagnostics Industry Structure 263
306. 8.2 Global Molecular Diagnostics Testing Market 264
307. 8.3 U.S. Molecular Diagnostics Testing Market 266
308. 8.4 European Molecular Diagnostics Market 267
309. 8.5 Japanese Molecular Diagnostics Testing Market 268
310. 8.6 Overview of the European Molecular Diagnostics Country Markets 268
311. 8.6.1 France 268
312. 8.6.2 Germany 268
313. 8.6.3 The United Kingdom 268
314. 8.6.4 Italy 269
315. 8.6.5 Spain 269
317. Appendix 1: Biowarfare Agents 270
320. LIST OF FIGURES
322. Figure 2.1: Segment of Double-Stranded DNA Showing the Base-Pair Relationship 16
323. Figure 3.1: Applications of Molecular Diagnostics Technology Platforms 30
324. Figure 3.2: Overall Structure of Nucleic Acid Testing Market 32
325. Figure 3.3: Serologic and Clinical Course of Acute HBV Infection 55
326. Figure 3.4: Primary Causes of Chronic Liver Disease 57
327. Figure 3.5: Combination Therapy in Typical HCV Infection 58
328. Figure 3.6: Time Course of Markers in Typical HCV Infection 59
329. Figure 3.7: Bacillus anthracis 108
330. Figure 8.1: Molecular Diagnostics Market Segmentation 262
331. Figure 8.2: Molecular Diagnostics Market Segmentation by Technology 263
332. Figure 8.3: Breakout of the Molecular Diagnostics Marketplace 265
333. Figure 8.4: U.S. Molecular Diagnostics Market Segments 2007 266
336. LIST OF TABLES
338. Table 3.1: Global Market for Molecular Diagnostics Testing, 2000 to 2012 33
339. Table 3.2: U.S. Market for Molecular Diagnostics Testing, 2004 to 2012 33
340. Table 3.3: Global Market for Nucleic Acid Testing, 2000 to 2012 34
341. Table 3.4: Summary of Molecular Diagnostics Testing 34
342. Table 3.5: Annual U.S. Market for DNA Probe Diagnostics, 1998 to 2012 35
343. Table 3.6: Annual Global Market for DNA Probe Diagnostics, 1998 to 2009 35
344. Table 3.7: Estimated Market Share of Major Competitors in U.S. DNA/PCR Kit Research Market 37
345. Table 3.8: Estimated Market Share of Major Competitors in U.S. DNA/PCR Kit Diagnostics Market 37
346. Table 3.9: Roche PCR Licenses 37
347. Table 3.10: DNA Probe Market Segments in the U.S. 38
348. Table 3.11: Companies Marketing Products Using DNA Probes 40
349. Table 3.12: Companies Marketing Multiple Products in Molecular Diagnostics Sector 40
350. Table 3.13: Global Sales of DNA Probe Kits, 1998 to 2005 41
351. Table 3.14: Companies Marketing DNA Detection Platforms 41
352. Table 3.15: Companies Marketing Genotyping Technologies 44
353. Table 3.16: Companies Marketing Clinical Genotyping Technologies 45
354. Table 3.17: Summary of Assays for HIV Viral Load Testing 51
355. Table 3.18: Global Market for HIV Diagnostic Testing, 2000 to 2012 53
356. Table 3.19: U.S. Market for HIV Diagnostic Testing, 2000 to 2012 53
357. Table 3.20: Serologic Diagnosis of HBV Infections* 55
358. Table 3.21: Unusual HBV Serologic Profiles Requiring Further Evaluation 56
359. Table 3.22: Recommendations for HBV Diagnostic Testing 56
360. Table 3.23: Lower Detection Limits of HBV DNA Assays 56
361. Table 3.24: Recommendations for HCV Diagnostic Testing 60
362. Table 3.25: Important HCV Statistics 60
363. Table 3.26: Global Market for HAV Diagnostic Testing, 2000 to 2008 62
364. Table 3.27: U.S. Market for HAV Diagnostic Testing, 2000 to 2008 63
365. Table 3.28: Global Market for HBV Diagnostic Testing, 2000 to 2008 63
366. Table 3.29: U.S. Market for HBV Diagnostic Testing, 2000 to 2008 63
367. Table 3.30: Global Market for HCV Diagnostic Testing, 2000 to 2008 63
368. Table 3.31: U.S. Market for HCV Diagnostic Testing, 2000 to 2008 64
369. Table 3.32: Global Market for SARS Diagnostics Testing, 2002 to 2008 65
370. Table 3.33: U.S. Market for SARS Diagnostics Testing, 2002 to 2008 65
371. Table 3.34: Global Market for Molecular Diagnostics Cancer Testing, 2000 to 2008 68
372. Table 3.35: Annual Volume of NAT Infectious Disease Testing, 2000 to 2008 72
373. Table 3.36: Global Market Dollar Volume of NAT STD Testing, 2000 to 2008 72
374. Table 3.37: U.S. Market Dollar Volume of NAT STD Testing, 2000 to 2009 72
375. Table 3.38: U.S. Market Share of NAT STD Testing 73
376. Table 3.39: Global Market for Chlamydia Diagnostic Testing, 2000 to 2009 73
377. Table 3.40: U.S. Market for Chlamydia Diagnostic Testing, 2000 to 2009 73
378. Table 3.41: Global Market for Gonorrhea Diagnostic Testing, 2000 to 2008 73
379. Table 3.42: Global Market for TB Diagnostic Testing, 2000 to 2008 74
380. Table 3.43: Global Market for DNA Group B Streptococcus Diagnostic Testing, 2000 to 2009 74
381. Table 3.44: U.S. Market for Group B Streptococcus Diagnostic Testing, 2000 to 2009 74
382. Table 3.45: Gen-Probe Clinical Diagnostic Products for the Detection of Non-Viral Micro-organisms 76
383. Table 3.46: Global Market for Blood-Screening Diagnostic Testing, 2000 to 2008 80
384. Table 3.47: U.S. Market for Blood-Screening Diagnostic Testing, 2000 to 2008 80
385. Table 3.48: Leading Players in SNP Genotyping 84
386. Table 3.49: Global Market for SNP Genotyping, 2000 to 2011 84
387. Table 3.50: DNA-Analysis Market Competitors 87
388. Table 3.51: Leading Companies in Medical Utility of SNPs 87
389. Table 3.52: Competitors in the Field of Identity Genomics Testing 88
390. Table 3.53: U.S. Market for Food-Screening Diagnostic Testing Using Molecular Diagnostics Techniques, 2000 to 2008 90
391. Table 3.54: Methods for Detection of Salmonella in Food Using Molecular Diagnostics Methods 91
392. Table 3.55: U.S. Market for Forensic Diagnostics Testing, 2000 to 2010 93
393. Table 3.56: U.S. Market for Biological Threat Detection Testing, 2000 to 2010 97
394. Table 3.57: Biotest Reagents 100
395. Table 3.58: Variation of CF Carrier Risks by Ethnic Group 111
396. Table 3.59: Reasons for CF Testing 111
397. Table 3.60: Variation of CF Detection Rates by Ethnic Background 111
398. Table 3.61: Global Market for CF Diagnostic Testing, 2000 to 2008 111
399. Table 3.62: U.S. Market for CF Diagnostic Testing, 2000 to 2008 111
400. Table 3.63: Commercial CF-Screening Products 112
401. Table 3.64: Emerging CF-Screening Products 112
402. Table 3.65: CF Screening Technology Summary 112
403. Table 3.66: U.S. Market for HLA Type Testing, 2000 to 2008 113
404. Table 3.67: Competitors in HLA Testing 114
405. Table 3.68: U.S. Market for NAT Genetic-Disease Testing, 2000 to 2008 115
406. Table 3.69: Non-U.S. Market for NAT Genetic-Disease Testing, 2000 to 2008 115
407. Table 3.70: U.S. Market for NAT Cytogenetic-Disease Testing, 2000 to 2008 115
408. Table 3.71: Non-U.S. Market for NAT Cytogenetic-Disease Testing, 2000 to 2008 115
409. Table 3.72: Carrier Rates of Common HFE Mutations in Caucasians 116
410. Table 3.73: Results and Diagnosis for Fragile X Syndrome 117
411. Table 3.74: Principal Competitors in Pharmacogenetics R&D for Personalized Medicine 121
412. Table 3.75: Principal Competitors in Pharmacogenetics Patient Testing 121
413. Table 4.1: DNA-Sequencing Market Players 128
414. Table 4.2: Global Market for DNA Chips, 2000 to 2007 128
415. Table 4.3: Top Ten Companies for Molecular Diagnostics Patents 146
416. Table 6.1: Companies Licensed to Sell Custom Molecular Beacon Probes 166
417. Table 6.2: U.S. Sample Preparation Market, 2005 to 2012 169
418. Table 7.1: Products Marketed by Abbott in the Diagnostics Market 173
419. Table 7.2: Summary of Selected Affymetrix Expression-Profiling Customers 177
420. Table 7.3: PACE Product Sales as a Percentage of Total Company Revenue, 2000 to 2005 213
421. Table 7.4: Innogenetics HLA Products for Genetic Testing and Transplantation 221
422. Table 7.5: Nanogen Product Sales, 2000 to 2006 233
423. Table 7.6: Rarely-Expressed Genes as Therapeutic Product Candidates 237
424. Table 7.7: Roche Diagnostics Key Products 251
425. Table 7.8: Sales by Region 252
426. Table 7.9: Sales by Business Area 252
427. Table 7.10: Product Line Sales 2005 252
428. Table 7.11: Growth Drivers 252
429. Table 8.1: Number of Molecular Diagnostics Tests in the U.S., 2000 to 2008 262
430. Table 8.2: Global Molecular Diagnostics Testing Revenues, 2000 to 2012 265
431. Table 8.3: Global Distribution of Molecular Diagnostics Testing 265
432. Table 8.4: U.S. Molecular Diagnostics Testing Market, 2004 to 2012 267
433. Table 8.5: European Molecular Diagnostics Testing Market, 2005 to 2012 267
434. Table 8.6: Japanese Molecular Diagnostics Testing Market, 2005 to 2012 268